Primer: Xuanzhu Biopharmaceutical (XUANZHU HK) - Nov 2025
Xuanzhu Biopharmaceutical is a clinical-stage biopharmaceutical company spun off from its controlling shareholder, Sihuan Pharmaceutical, with...
103 Views
Xuanzhu Biopharm (轩竹生物科技) IPO: Trading Updates
Xuanzhu raises $100m in global offering, set to list on HK Stock Exchange on Oct 15th. We provide updated IPO details before trading debut.
256 Views
Xuanzhu Biopharma IPO: Lacks Product Differentiation, Investors Can Give It a Pass For Now
Xuanzhu Biopharmaceutical files for IPO to raise HK$781M. 2026 is a crucial year for the company's commercialization efforts. Lacks product...
290 Views
Xuanzhu Biopharm (轩竹生物科技) IPO: Spin off at a Premium
China-based biopharm Xuanzhu launches IPO in Hong Kong to raise at least $100 million, but deal terms are seen as overvalued and lacking...
541 Views
Pre-IPO Xuanzhu Biopharmaceutical (PHIP Updates) - Some Points Worth the Attention
Xuanzhu faces tough competition, leading to doubts about its commercialization outlook. The peak sales of three core products could be RMB800mn...
451 Views